These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23879463)

  • 1. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
    Anglin JL; Song Y
    J Med Chem; 2013 Nov; 56(22):8972-83. PubMed ID: 23879463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L.
    Anglin JL; Deng L; Yao Y; Cai G; Liu Z; Jiang H; Cheng G; Chen P; Dong S; Song Y
    J Med Chem; 2012 Sep; 55(18):8066-74. PubMed ID: 22924785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L.
    Gibbons GS; Owens SR; Fearon ER; Nikolovska-Coleska Z
    ACS Chem Biol; 2015 Jan; 10(1):109-14. PubMed ID: 25361163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
    Liu W; Deng L; Song Y; Redell M
    PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
    Bernt KM; Zhu N; Sinha AU; Vempati S; Faber J; Krivtsov AV; Feng Z; Punt N; Daigle A; Bullinger L; Pollock RM; Richon VM; Kung AL; Armstrong SA
    Cancer Cell; 2011 Jul; 20(1):66-78. PubMed ID: 21741597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.
    Yi Y; Ge S
    J Hematol Oncol; 2022 Mar; 15(1):35. PubMed ID: 35331314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The upstreams and downstreams of H3K79 methylation by DOT1L.
    Vlaming H; van Leeuwen F
    Chromosoma; 2016 Sep; 125(4):593-605. PubMed ID: 26728620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
    Daigle SR; Olhava EJ; Therkelsen CA; Majer CR; Sneeringer CJ; Song J; Johnston LD; Scott MP; Smith JJ; Xiao Y; Jin L; Kuntz KW; Chesworth R; Moyer MP; Bernt KM; Tseng JC; Kung AL; Armstrong SA; Copeland RA; Richon VM; Pollock RM
    Cancer Cell; 2011 Jul; 20(1):53-65. PubMed ID: 21741596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L.
    Basavapathruni A; Jin L; Daigle SR; Majer CR; Therkelsen CA; Wigle TJ; Kuntz KW; Chesworth R; Pollock RM; Scott MP; Moyer MP; Richon VM; Copeland RA; Olhava EJ
    Chem Biol Drug Des; 2012 Dec; 80(6):971-80. PubMed ID: 22978415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diverse functions of Dot1 and H3K79 methylation.
    Nguyen AT; Zhang Y
    Genes Dev; 2011 Jul; 25(13):1345-58. PubMed ID: 21724828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.
    Wu F; Nie S; Yao Y; Huo T; Li X; Wu X; Zhao J; Lin YL; Zhang Y; Mo Q; Song Y
    Theranostics; 2021; 11(17):8172-8184. PubMed ID: 34373735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer.
    Zhang L; Deng L; Chen F; Yao Y; Wu B; Wei L; Mo Q; Song Y
    Oncotarget; 2014 Nov; 5(21):10665-77. PubMed ID: 25359765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells.
    Steger DJ; Lefterova MI; Ying L; Stonestrom AJ; Schupp M; Zhuo D; Vakoc AL; Kim JE; Chen J; Lazar MA; Blobel GA; Vakoc CR
    Mol Cell Biol; 2008 Apr; 28(8):2825-39. PubMed ID: 18285465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
    Deshpande AJ; Chen L; Fazio M; Sinha AU; Bernt KM; Banka D; Dias S; Chang J; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
    Blood; 2013 Mar; 121(13):2533-41. PubMed ID: 23361907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79.
    Chen S; Yang Z; Wilkinson AW; Deshpande AJ; Sidoli S; Krajewski K; Strahl BD; Garcia BA; Armstrong SA; Patel DJ; Gozani O
    Mol Cell; 2015 Oct; 60(2):319-27. PubMed ID: 26439302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging roles of DOT1L in leukemia and normal development.
    McLean CM; Karemaker ID; van Leeuwen F
    Leukemia; 2014 Nov; 28(11):2131-8. PubMed ID: 24854991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies.
    Yao Y; Chen P; Diao J; Cheng G; Deng L; Anglin JL; Prasad BV; Song Y
    J Am Chem Soc; 2011 Oct; 133(42):16746-9. PubMed ID: 21936531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development.
    Barry ER; Corry GN; Rasmussen TP
    Expert Opin Ther Targets; 2010 Apr; 14(4):405-18. PubMed ID: 20230194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.
    Wong M; Polly P; Liu T
    Am J Cancer Res; 2015; 5(9):2823-37. PubMed ID: 26609488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.